Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Basic) (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of EPS (Basic) readings, the most recent being $1.54 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 49.51% to $1.54 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.82, a 42.6% increase, with the full-year FY2025 number at $4.81, up 41.47% from a year prior.
  • EPS (Basic) hit $1.54 in Q4 2025 for Neurocrine Biosciences, down from $2.11 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.11 in Q3 2025 to a low of -$0.79 in Q1 2023.
  • Median EPS (Basic) over the past 5 years was $0.68 (2024), compared with a mean of $0.67.
  • Biggest five-year swings in EPS (Basic): skyrocketed 1250.0% in 2022 and later tumbled 626.67% in 2023.
  • Neurocrine Biosciences' EPS (Basic) stood at -$0.08 in 2021, then skyrocketed by 1250.0% to $0.92 in 2022, then soared by 64.13% to $1.51 in 2023, then tumbled by 31.79% to $1.03 in 2024, then surged by 49.51% to $1.54 in 2025.
  • The last three reported values for EPS (Basic) were $1.54 (Q4 2025), $2.11 (Q3 2025), and $1.09 (Q2 2025) per Business Quant data.